Last week the House of Commons Select Committee published its report on the impact Brexit may have on medicines, medical devices and substances of human origins, advocating very close regulatory alignment. You can read more on the report, its conclusions, and what life sciences companies need to do to prepare, on our Brexit blog.
Last week the House of Commons Select Committee published its report on the impact Brexit may have on medicines, medical devices and substances of human origins, advocating very close regulatory alignment.